Tastemaker Acquisition Corp. appointed Oleg Grodnensky as new CEO

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. 


Effective July 3, 2023, (i) David Pace and Andrew Pforzheimer resigned as Co-Chief Executive Officers of Tastemaker Acquisition Corp., a Delaware corporation (the "Company"), and as members of the board of directors of the Company (the "Board"), (ii) Gregory Golkin resigned as President of the Company and as a member of the Board, (iii) Christopher Bradley resigned as Chief Financial Officer and Secretary of the Company, and (iv) Daniel Fleischmann resigned as Chief Strategy Officer of the Company.


Additionally, effective July 3, 2023, the Company's independent directors, Harold Rosser, Rick Federico, Starlette Johnson and Andrew Heyer, resigned as members of the Board and from all committees thereof on which he or she served. There were no disagreements between the Company and any of these individuals.


Effective July 3, 2023, the Company appointed Oleg Grodnensky, age 46, as Chief Executive Officer and Chairman of the Board.


Mr. Grodnensky is a repeat sponsor and a Managing Partner at Priveterra Capital, a strategic opportunity investments fund focusing on opportunities across healthcare and financial technology sectors. Priveterra Capital is also a majority sponsor of Priveterra Acquisition Corp. where Mr. Grodnensky currently serves as Chief Financial Officer, Chief Operating Officer and Secretary. On July 3rd, 2023 shareholders of Priveterra Acquisition Corp. approved its business combination with AEON Biopharma, Inc. and transaction is expected to close in July 2023. He received his BS in Economics and Mathematics from Duke University in 1998.


There are no arrangements or understandings between Mr. Grodnensky and any other person pursuant to which he was selected to serve as Chief Executive Officer of the Company or on the Board. There are also no transactions or relationships between Mr. Grodnensky and the Company that would require disclosure under Item 404(a) of Regulation S-K.


Effective July 5, 2023, the Company elected Bill Carpou, Dimitri Azar and Cameron Piron to serve as independent members of the Board. Each of Messrs. Carpou, Azar and Piron is expected to serve on the Audit Committee and Compensation Committee of the Company.


Mr. Carpou serves as the Chief Executive Officer of OCTANe and a partner at Visionary Ventures, a firm he founded in April 2015. Prior to joining OCTANe, Mr. Carpou founded TheGreyGroup and served as its Managing Partner, focusing on revenue growth and operational improvement.


Dr. Azar serves as President and Chief Executive Officer of Twenty/Twenty Therapeutics, which was formed in August 2020 as a joint venture between Verily Life Sciences and Santen Pharmaceutical. Prior to this role, Dr. Azar served as Senior Director of Ophthalmic Innovations for Verily Life Sciences. He is currently Distinguished Professor of Ophthalmology and served as Dean of the University of Illinois College of Medicine from 2011 to 2018. Dr. Azar was also a Professor of Ophthalmology at Harvard Medical School from 2003 to 2006.


Mr. Piron co-founded Synaptive Medical, Inc. in April 2012 and currently serves as its President, Chief Strategy Officer and a member of its board of directors. Prior to these roles, he served as its Chief Executive Officer and Chairman. Since 2010, Mr. Pirone has also served as a member of the board of directors of Conavi Medical and Orthogonal, Inc.


In connection with their election to the Board, each of Messrs. Carpou, Azar and Piron is expected to be allocated interests in Tastemaker Sponsor LLC, the Company's sponsor, representing 25,000 shares of Class B common stock, subject to certain terms and conditions. In addition, each of Messrs. Carpou, Azar and Piron entered into an indemnity agreement, which is substantially similar to the form of indemnity agreement filed as Exhibit 10.7 to the Company's annual report on Form 10-K for the year ended December 31, 2022.


There are no arrangements or understandings between any of Messrs. Carpou, Azar or Piron and any other person pursuant to which each was selected to serve on the Board. There are also no transactions or relationships between any of Messrs. Carpou, Azar or Piron and the Company that would require disclosure under Item 404(a) of Regulation S-K.